Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024

収録刊行物

• MMWR. Morbidity and Mortality Weekly Report

  MMWR. Morbidity and Mortality Weekly Report 73 (4), 77-83, 2024-02-01

  Centers for Disease Control MMWR Office